The corporate’s inventory has zoomed this 12 months, pushed by the explosive progress of the weight-loss drug market.
Printed On 21 Nov 2025
Eli Lilly has hit $1 trillion in market worth, making it the primary drugmaker to enter the unique membership dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
A greater than 35 % rally within the firm’s inventory this 12 months has largely been pushed by the explosive progress of the weight-loss drug market and noticed it be part of the $1 trillion membership on Friday.
Really helpful Tales
record of 4 objectsfinish of record
As soon as seen as a distinct segment class, weight problems remedies are actually one of the crucial profitable segments in healthcare, with steadily rising demand.
Novo Nordisk had the early lead within the area, however Lilly’s medication – Mounjaro and Zepbound – have surged in reputation and helped eclipse its rival in prescriptions.
The corporate’s shares had been up 1.3 % at a file excessive of $1,057.70.
Lilly now trades at one of many richest valuations in large pharma, at about 50 occasions its anticipated earnings over the subsequent 12 months, in line with LSEG knowledge, reflecting traders’ perception that demand for weight problems medication will stay sturdy.
Shares have additionally far outpaced the broader United States fairness market. Because the launch of Zepbound in late 2023, Lilly has gained greater than 75 %, in contrast with a greater than 50 % rise within the S&P 500 over the identical interval.
Within the newest reported quarter, Lilly posted mixed income of greater than $10.09bn from its weight problems and diabetes portfolio, accounting for greater than half of its complete income of $17.6bn.
“They’re doing so many issues outdoors of weight problems, however to recommend something is driving share value past weight problems at this level, I don’t know if that might be a factual assertion,” stated Kevin Gade, chief working officer at Lilly shareholder Bahl and Gaynor, prematurely of the milestone.
‘Gross sales phenomenon’
Wall Avenue estimates the weight-loss drug market to be price $150bn by 2030, with Lilly and Novo collectively controlling nearly all of projected international gross sales.
Buyers are actually centered on Lilly’s oral weight problems drug, orforglipron, which is predicted to be accepted early subsequent 12 months.
In a observe final week, Citi analysts stated the most recent technology of GLP-1 medication have already been a “gross sales phenomenon”, and orforglipron is poised to learn from the “inroads made by its injectable predecessors”.
Lilly’s latest deal with the White House to cut prices for its weight-loss drugs, in addition to deliberate investments to increase drug manufacturing, augur properly for its progress.
Lilly is beginning to resemble the “Magnificent Seven” once more, stated James Shin, director of Biopharma Fairness Analysis at Deutsche Financial institution, referring to the seven tech heavyweights, together with Nvidia and Microsoft, which have powered a lot of the market’s returns this 12 months.
At one level, traders seen it as a part of that elite group, however after some disappointing headlines and earnings, it slipped out of favour.
Now, nevertheless, it appears poised to rejoin that circle, probably even as a substitute for traders, particularly given latest considerations and weak point in some AI shares, he added.
Nonetheless, analysts and traders are watching whether or not Lilly can maintain its present progress as costs of Mounjaro and Zepbound come below strain, and whether or not its scale-up plans, together with its diversified pipeline and dealmaking, will offset margin strain.
